Bristol-Myers Squibb stock holds steady as analysts adjust price targets

Published on 09/20/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol-Myers Squibb stock recently closed at USD 63.06 on September 18, 2026, sitting below its 52-week high but well above the low. Analysts at B of A Securities and Cantor Fitzgerald have updated their price targets, offering a mixed but detailed view on the shares.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol-Myers Squibb Company (ISIN US1078421011) stock last closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, placing the shares between their 52-week low of USD 42.53 and high of USD 68.64 and signaling a mid-range position in the recent trading band.

Analysts fine-tune views on Bristol-Myers Squibb

According to Scanx Trade on September 19, 2026, B of A Securities analyst Tim Anderson maintains a Buy rating on Bristol-Myers Squibb but has trimmed the price target to USD 66 from USD 67, a modest reduction that still sits above the latest closing price.

The same overview from Scanx Trade also notes that Cantor Fitzgerald analyst Carter Gould reiterates a Neutral rating with a price target of USD 54, which stands clearly below both the B of A target and the recent share price and underlines a more cautious stance on the stock.

Recent price levels and trading context

Data compiled by Forbes show that Bristol-Myers Squibb shares closed at USD 63.06 on September 18, 2026, after trading between an intraday low of USD 62.19 and a high of USD 63.06, with volume of 36,576,219 shares.

In an earlier session, as reported by Ad-hoc-news, the stock closed at USD 62.84 on September 17, 2026, with its 52-week range stated as USD 42.53 to USD 68.64 and a market capitalization of about USD 129.46 billion as of that date, leaving the shares roughly 8.4 percent below the 52-week high but comfortably above the lower bound.

Earnings backdrop and valuation signals

While the latest detailed quarterly figures are not restated in full in the recent hits, valuation and consensus data provide additional context for investors. The stock overview from Forbes cites a consensus revenue estimate of USD 48.62 billion and a consensus earnings-per-share estimate of USD 6.44 for the current fiscal year, framing expectations against which upcoming results will be judged.

The same Ad-hoc-news article pointing to results scheduled for October 29, 2026, highlights that Bristol-Myers Squibb trades at a forward price-earnings multiple that, according to referenced portal Mitrade, stands below that of key peer AbbVie, suggesting that the stock is valued more conservatively relative to some competitors in the large-cap pharmaceuticals space.

As Zacks data summarized in the Ad-hoc-news piece indicate, the 2026 earnings-per-share estimate for Bristol-Myers Squibb was recently lifted to USD 6.91 from USD 6.34 over the previous 60 days, while the 2027 estimate moved to USD 6.46 from USD 6.12, signaling that analyst expectations have been revised upward in the near term despite the mixed rating profile.

Next catalyst: upcoming results

Investors are now looking ahead to the next earnings release, with Ad-hoc-news citing October 29, 2026 as the scheduled date for Bristol-Myers Squibb to present its latest quarterly figures, a moment likely to test whether the current consensus for revenue near USD 48.62 billion and EPS above USD 6.4 can be delivered or exceeded.

Against this backdrop of adjusted price targets and rising earnings estimates, the positioning of Bristol-Myers Squibb stock between its 52-week low and high suggests room for movement once the company provides fresh operational data and guidance, particularly given the spread between the more optimistic USD 66 target from B of A Securities and the more cautious USD 54 target from Cantor Fitzgerald.

Stock price snapshot

As of the close on September 18, 2026, Bristol-Myers Squibb stock traded at USD 63.06 on the New York Stock Exchange, within its 52-week range of USD 42.53 to USD 68.64 and corresponding to a market capitalization of about USD 129.46 billion as last reported on September 17, 2026.